T 0414/18 (Compositions comprising rilpiverin/GILEAD) of 21.05.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T041418.20210521
- Date of decision
- 21 May 2021
- Case number
- T 0414/18
- Online on
- 14 June 2021
- Petition for review of
- -
- Application number
- 11791161.0
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRIN HCL AND TENOVOFIR DISOPROXIL FUMARATE
- Applicant name
- Gilead Sciences, Inc.
Janssen Sciences Ireland UC - Opponent name
- LEK Pharmaceuticals d.d.
HGF Limited - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56European Patent Convention Art 84European Patent Convention Art 54European Patent Convention Art 87
- Keywords
- Inventive step - effect not made credible within the whole scope of claim
Inventive step - Main request and auxiliary requests 2, 4, 6-8, 10, 11
Inventive step - auxiliary request 12 (yes)
Claims - clarity after amendment (no)
Claims - auxiliary requests 1, 3, 5, 9
Claims - clarity after amendment (yes)
Claims - auxiliary request 12
Novelty - public prior use (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed